V. Hoff, D. Turner, and J. , Response rates, duration of response, and dose response effects in phase I studies of antineoplastics, Investigational New Drugs, vol.9, issue.1, pp.115-137, 1991.
DOI : 10.1007/BF00194562

V. Murthy, H. Krumholz, and C. Gross, Participation in Cancer Clinical Trials, JAMA, vol.291, issue.22, pp.2720-2726, 2004.
DOI : 10.1001/jama.291.22.2720

J. Seidenfeld, E. Horstmann, E. Emanuel, and C. Grady, Participants in phase 1 oncology research trials: are they vulnerable? Arch Intern Med, pp.16-20, 2008.

S. Kummar, M. Gutierrez, J. Doroshow, and A. Murgo, Drug development in oncology: classical cytotoxics and molecularly targeted agents, British Journal of Clinical Pharmacology, vol.4, issue.1, pp.15-26, 2006.
DOI : 10.1182/blood-2002-05-1361

P. Lorusso, S. Boerner, and L. Seymour, An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics. Clin Cancer Res, pp.1710-1718, 2010.

E. Korn, S. Arbuck, J. Pluda, R. Simon, R. Kaplan et al., Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?, Journal of Clinical Oncology, vol.19, issue.1, pp.265-72, 2001.
DOI : 10.1200/JCO.2001.19.1.265

S. Cannistra, Challenges and Pitfalls of Combining Targeted Agents in Phase I Studies, Journal of Clinical Oncology, vol.26, issue.22, pp.3665-3672, 2008.
DOI : 10.1200/JCO.2008.17.2676

X. Paoletti, S. Postel-vinay, V. Servois, A. Doussau, L. Ollivier et al., Méthodes pour la recherche de dose de traitements ciblés : nouvelles pistes, Bull Cancer, vol.97, issue.12, pp.1485-95, 2010.

J. Dancey and H. Chen, Strategies for optimizing combinations of molecularly targeted anticancer agents, Nature Reviews Drug Discovery, vol.22, issue.8, pp.649-59, 2006.
DOI : 10.1038/nrd2089

B. Druker, M. Talpaz, D. Resta, B. Peng, E. Buchdunger et al., Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia, New England Journal of Medicine, vol.344, issue.14, pp.1031-1038, 2001.
DOI : 10.1056/NEJM200104053441401

G. Demetri, M. Von-mehren, C. Blanke, A. Van-den-abbeele, B. Eisenberg et al., Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors, New England Journal of Medicine, vol.347, issue.7, pp.472-80, 2002.
DOI : 10.1056/NEJMoa020461

S. Soverini and . Abl, ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia, Journal of Clinical Oncology, vol.23, issue.18, pp.4100-4109, 2005.
DOI : 10.1200/JCO.2005.05.531

H. Kantarjian, Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood, pp.473-478, 2002.

D. Jonker, O. Callaghan, C. Karapetis, C. Zalcberg, J. Tu et al., Cetuximab for the Treatment of Colorectal Cancer, New England Journal of Medicine, vol.357, issue.20, pp.2040-2048, 2007.
DOI : 10.1056/NEJMoa071834

C. Karapetis, S. Khambata-ford, D. Jonker, O. Callaghan, C. Tu et al., Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer, New England Journal of Medicine, vol.359, issue.17, pp.1757-65, 2008.
DOI : 10.1056/NEJMoa0804385

J. Masters and B. Köberle, Curing metastatic cancer: lessons from testicular germ-cell tumours, Nature Reviews Cancer, vol.275, issue.7, pp.517-542, 2003.
DOI : 10.1038/nrc1120

C. Paller, P. Bradbury, S. Ivy, L. Seymour, P. Lorusso et al., Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee, Clinical Cancer Research, vol.20, issue.16, pp.4210-4217, 2014.
DOI : 10.1158/1078-0432.CCR-14-0521

J. Johnson, S. Decker, D. Zaharevitz, L. Rubinstein, J. Venditti et al., Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials, British Journal of Cancer, vol.84, issue.10, p.1424, 2001.
DOI : 10.1054/bjoc.2001.1796

T. Chou, Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies, Pharmacological Reviews, vol.58, issue.3, pp.621-81, 2006.
DOI : 10.1124/pr.58.3.10

S. Park, M. Davis, J. Doroshow, and S. Kummar, Safety and feasibility of targeted agent combinations in solid tumours, Nature Reviews Clinical Oncology, vol.28, issue.3, pp.154-68, 2013.
DOI : 10.1038/nrclinonc.2012.245

L. Tourneau, C. Lee, J. Siu, and L. , Dose Escalation Methods in Phase I Cancer Clinical Trials, JNCI Journal of the National Cancer Institute, vol.101, issue.10, pp.708-728, 2009.
DOI : 10.1093/jnci/djp079

É. Chatelut, Pharmacologie des dérivés du platine: différences entre les trois composés et les facteurs de variabilité entre patients, Bull Cancer, vol.98, issue.11, pp.1253-61, 2011.

A. Pick and K. Nystrom, Pazopanib for the Treatment of Metastatic Renal Cell Carcinoma, Clinical Therapeutics, vol.34, issue.3, pp.511-531
DOI : 10.1016/j.clinthera.2012.01.014

R. Jain, D. Duda, J. Clark, and J. Loeffler, Lessons from phase III clinical trials on anti-VEGF therapy for cancer, Nature Clinical Practice Oncology, vol.25, issue.1, pp.24-40, 2006.
DOI : 10.1038/ncponc0403

C. Tourneau, J. Lee, and L. Siu, Dose Escalation Methods in Phase I Cancer Clinical Trials, JNCI Journal of the National Cancer Institute, vol.101, issue.10, pp.708-728, 2009.
DOI : 10.1093/jnci/djp079

P. Hamberg, M. Ratain, E. Lesaffre, and J. Verweij, Dose-escalation models for combination phase I trials in oncology, European Journal of Cancer, vol.46, issue.16, pp.2870-2878, 2010.
DOI : 10.1016/j.ejca.2010.07.002

J. Harrington, G. Wheeler, M. Sweeting, A. Mander, and D. Jodrell, Adaptive designs for dual-agent phase I dose-escalation studies, Nature Reviews Clinical Oncology, vol.63, issue.5, pp.277-88, 2013.
DOI : 10.1038/nrclinonc.2013.35

H. Hurwitz, A. Dowlati, S. Saini, S. Savage, A. Suttle et al., Phase I Trial of Pazopanib in Patients with Advanced Cancer. Clin Cancer Res, Jun, vol.1515, issue.12, pp.4220-4227, 2009.

G. Sonpavde and T. Hutson, Pazopanib: A novel multitargeted tyrosine kinase inhibitor, Current Oncology Reports, vol.23, issue.16S, pp.115-124, 2007.
DOI : 10.1007/s11912-007-0007-2

P. Hamberg, J. Verweij, and S. Sleijfer, Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor. The Oncologist, 2010.

T. Brotelle and J. Bay, Intérêt du pazopanib dans le traitement des cancers du rein et des sarcomes des tissus mous, Bull Cancer, vol.101, issue.6, pp.641-647, 2014.

R. Van-geel, J. Beijnen, and J. Schellens, Concise Drug Review: Pazopanib and Axitinib. The Oncologist, pp.1081-1090, 2012.

Y. Deng, C. Sychterz, A. Suttle, M. Dar, D. Bershas et al., Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer, Xenobiotica, vol.84, issue.5, pp.443-53, 2013.
DOI : 10.3109/00498254.2012.734642

R. Van-geel, J. Beijnen, and J. Schellens, Concise Drug Review: Pazopanib and Axitinib. The Oncologist, pp.1081-1090, 2012.

C. Sternberg, R. Hawkins, J. Wagstaff, P. Salman, J. Mardiak et al., A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update, European Journal of Cancer, vol.49, issue.6, pp.1287-96
DOI : 10.1016/j.ejca.2012.12.010

R. Motzer, T. Hutson, D. Cella, J. Reeves, R. Hawkins et al., Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.369, issue.8, pp.722-753, 2013.
DOI : 10.1056/NEJMoa1303989

B. Escudier, C. Porta, P. Bono, T. Powles, T. Eisen et al., Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study, Journal of Clinical Oncology, vol.32, issue.14, pp.1412-1420, 2014.
DOI : 10.1200/JCO.2013.50.8267

B. Monk, L. Lopez, J. Zarba, A. Oaknin, C. Tarpin et al., Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer, Journal of Clinical Oncology, vol.28, issue.22, pp.3562-3571, 2010.
DOI : 10.1200/JCO.2009.26.9571

H. Burris, A. Dowlati, R. Moss, J. Infante, S. Jones et al., Phase I Study of Pazopanib in Combination with Paclitaxel and Carboplatin Given Every 21 Days in Patients with Advanced Solid Tumors, Molecular Cancer Therapeutics, vol.11, issue.8, pp.1820-1828, 2012.
DOI : 10.1158/1535-7163.MCT-11-0997

H. Burger, A. Zoumaro-djayoon, A. Boersma, J. Helleman, E. Berns et al., Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2), British Journal of Pharmacology, vol.379, issue.2, pp.898-908, 2010.
DOI : 10.1111/j.1476-5381.2009.00569.x

P. Daley-yates and D. Mcbrien, The mechanism of renal clearance of cisplatin (cis-dichlorodiammine platinum II) and its modification by furosemide and probenecid, Biochemical Pharmacology, vol.31, issue.13, pp.2243-2249, 1982.
DOI : 10.1016/0006-2952(82)90108-3

W. Lieberthal, V. Triaca, and J. Levine, Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis, Am J Physiol -Ren Physiol, vol.270, issue.4, pp.700-708, 1996.

E. Ellebaek and J. Herrstedt, Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy, Current Opinion in Supportive and Palliative Care, vol.2, issue.1, pp.28-34, 2008.
DOI : 10.1097/SPC.0b013e3282f44a75

L. Rybak, C. Whitworth, D. Mukherjea, and V. Ramkumar, Mechanisms of cisplatin-induced ototoxicity and prevention, Hearing Research, vol.226, issue.1-2, pp.157-67, 2007.
DOI : 10.1016/j.heares.2006.09.015

M. Aapro and C. Walko, Aprepitant: drug-drug interactions in perspective, Annals of Oncology, vol.21, issue.12, pp.2316-2339, 2010.
DOI : 10.1093/annonc/mdq149

S. Nakade, T. Ohno, J. Kitagawa, Y. Hashimoto, M. Katayama et al., Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting, Cancer Chemotherapy and Pharmacology, vol.68, issue.1, pp.75-83, 2008.
DOI : 10.1007/s00280-008-0713-y

S. Chawla, S. Grunberg, R. Gralla, P. Hesketh, C. Rittenberg et al., Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting, Cancer, vol.42, issue.9, pp.2290-300, 2003.
DOI : 10.1002/cncr.11320

P. Nygren, K. Hande, K. Petty, M. Fedgchin, K. Dyck et al., Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients, Cancer Chemotherapy and Pharmacology, vol.36, issue.6, pp.609-625, 2005.
DOI : 10.1007/s00280-004-0946-3

M. Aapro and C. Walko, Aprepitant: drug-drug interactions in perspective, Annals of Oncology, vol.21, issue.12, pp.2316-2339, 2010.
DOI : 10.1093/annonc/mdq149

A. Jubb, A. Oates, S. Holden, and H. Koeppen, Predicting benefit from anti-angiogenic agents in malignancy, Nature Reviews Cancer, vol.8, issue.8, pp.626-661, 2006.
DOI : 10.1038/nrc1946

T. Hutson, I. Davis, J. Machiels, D. Souza, P. Rottey et al., Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.28, issue.3, pp.475-80, 2010.
DOI : 10.1200/JCO.2008.21.6994

S. Urien and F. Lokiec, Population pharmacokinetics of total and unbound plasma cisplatin in adult patients, British Journal of Clinical Pharmacology, vol.38, issue.6, pp.756-63, 2004.
DOI : 10.1046/j.1365-2125.1996.04231.x

D. Imbs, S. Négrier, P. Cassier, A. Hollebecque, A. Varga et al., Pharmacokinetics of pazopanib administered in combination with bevacizumab, Cancer Chemotherapy and Pharmacology, vol.37, issue.Suppl 1, pp.1189-96
DOI : 10.1007/s00280-014-2455-3

M. Pera and H. Harder, Analysis for platinum in biological material by flameless atomic absorption spectrometry, Clin Chem, vol.23, issue.7, pp.1245-1254, 1977.

K. Wu, L. House, J. Ramírez, M. Seminerio, and M. Ratain, Evaluation of Utility of Pharmacokinetic Studies in Phase I Trials of Two Oncology Drugs. Clin Cancer Res, pp.6039-6082, 2013.

S. Ekins, S. Andreyev, A. Ryabov, E. Kirillov, E. Rakhmatulin et al., A COMBINED APPROACH TO DRUG METABOLISM AND TOXICITY ASSESSMENT, Drug Metabolism and Disposition, vol.34, issue.3, pp.495-503, 2006.
DOI : 10.1124/dmd.105.008458

J. Hirth, P. Watkins, M. Strawderman, A. Schott, R. Bruno et al., The Effect of an Individual's Cytochrome CYP3A4 Activity on Docetaxel Clearance, Clin Cancer Res, vol.6, issue.4, pp.1255-1263, 2000.

B. Vincenzi, G. Tonini, and D. Santini, Aprepitant for Erlotinib-Induced Pruritus, New England Journal of Medicine, vol.363, issue.4, pp.397-405, 2010.
DOI : 10.1056/NEJMc1003937

A. Bonetti, T. Franceschi, P. Apostoli, A. Messori, L. Sperotto et al., Cisplatin Pharmacokinetics Using a Five-Day Schedule During Repeated Courses of Chemotherapy in Germ Cell Tumors, Therapeutic Drug Monitoring, vol.17, issue.1, pp.25-32, 1995.
DOI : 10.1097/00007691-199502000-00005

B. Suttle, H. Ball, M. Molimard, D. Rajagopalan, R. Swann et al., Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC) ASCO Meet Abstr, p.3048, 2010.